Emerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets

 


Emerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets is a very dynamic field undergoing many changes. This research service includes in depth analysis of the total market as well as the cytoxic and targeted therapy markets. This analysis includes patient forecasts, revenue forecasts, product/pipeline analysis and oncologist's perspectives on the new cancer fighting mechanisms.

Regular Price: USD 2,450

Special Price USD 1,715

30% OFF

* Required Fields

Regular Price: USD 2,450

Special Price USD 1,715

PAY BY INVOICE

Be the first to review this product

Table of Contents

Emerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets, U.S. Total Market Overview for NSCLCExecutive SummaryExecutive SummaryResearch Scope and SegmentationScope and SegmentationResearch MethodologyDisease OverviewIntroductionEtiologyDiagnosis and StagingTreatment OverviewPatient ForecastPatient Incidence ForecastPatients per Line of TherapyPatient Forecast of Untreated PatientsLine of Therapy Revenue ForecastsMarket Engineering MeasurementsRevenue Forecasts for First Line TherapyRevenue Forecasts for Second Line TherapyRevenue Forecasts for Third Line Therapy and Unmet Need PopulationGeneral Market TrendsIndustry ChallengesMarket DriversMarket RestraintsOncologists' Perspectives on Current and Future NSCLC TherapiesFrost & Sullivan AwardsCustomer Service Leadership AwardCompany of the Year AwardTechnology Innovation AwardProduct of the Year AwardEmerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets, U.S. Cytotoxic Markets for NSCLCOverviewIntroductionMarket Engineering MeasurementsForecasts and TrendsTreatment Protocols and Cost per CycleRevenue ForecastsCompetitive AnalysisCompetitive StructureMarket Share AnalysisProduct AnalysisPipeline AnalysisEmerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets, U.S. Targeted Therapies Markets for NSCLCOverviewIntroductionMarket Engineering MeasurementsTreatment Protocols and Cost of TherapyRevenue Forecasts for Targeted TherapiesEGF PathwayMechanism of ActionProduct AnalysisPipeline AnalysisRevenue ForecastsAngiogenesisMechanism of ActionPipeline AnalysisRevenue ForecastsCell Proliferation/Apoptosis PathwayMechanism of ActionPipeline AnalysisRevenue ForecastImmune Response PathwayMechanism of ActionPipeline AnalysisRevenue ForecastsCompetitive AnalysisCompetitive StructureMarket Share AnalysisEmerging Therapeutics in the U.S. Non-small Cell Lung Cancer Markets, AppendixDecision Support DatabasePhysiciansTotal Male PopulationTotal Female PopulationPrevalence of Male SmokersPrevalence of Female SmokersPopulation of Age 65 or Older




Related Research

Release Date : 11-Aug-17

Region : North America

Release Date : 10-Aug-17

Region : North America

Release Date : 09-Aug-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.